PFE Feb 2023 55.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.8000

0.0000

(0.00%)

As of 12:32PM EDT. Market open.

Loading interactive chart…

Editor's pick
Yahoo Finance Video
UK approves COVID vaccine that targets Omicron subvariants
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
Motley Fool
1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)
On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.
Zacks
Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.